# 1 Title page

- 2 Main title: Evaluating the Safety Profile of the CoronaVac in Adult and Elderly populations: A Phase IV
- **3** Prospective Observational Study in Brazil
- 4 Short-title: Safety profile of CoronaVac in Brazil
- 5 Authors and affiliations: Monica Akissue de Camargo Teixeira Cintra<sup>1</sup>, Eder Gatti Fernandes<sup>1</sup>, Vanessa Infante<sup>1</sup>,
- 6 Ana Paula Loch<sup>1</sup>, Lucas Ragiotto<sup>1</sup>, Patrícia Emília Braga<sup>1</sup>, Maria da Graça Salomão<sup>1</sup>, Maria Beatriz Bastos
- 7 Lucchesi<sup>1</sup>, Mayra Martho Moura de Oliveira<sup>1</sup>, Vera Lúcia Gattás<sup>1</sup>, Anderson Soares da Silva<sup>2</sup>, Paulo José Fortes
- 8 Villas Boas<sup>3</sup>, Marta Heloisa Lopes<sup>4</sup>, José Moreira<sup>1\*</sup>, Fernanda Castro Boulos<sup>1</sup>, CFV-01-IB study group<sup>#</sup>
- 9 <sup>1</sup>Clinical Trials and Pharmacovigilance Center, Instituto Butantan, São Paulo, Brazil.
- 10 <sup>2</sup> Centro de Saúde Escola da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP-
- 11 USP) Dr. Joel Domingos Machado.
- 12 <sup>3</sup> Centro de Saúde Escola da Faculdade de Medicina de Botucatu Unesp.
- <sup>4</sup> Centro de Referência de Imunobiológicos Especiais Hospital das Clínicas da Faculdade de Medicina da
  Universidade de São Paulo (CRIE-HCFMUSP).
- 15 #Members of the CFV-01-IB study group are listed in the Supplementary Appendix
- 16 Corresponding author: José Moreira, MD, PhD, Clinical Developmental Medical Director, Center of Clinical
- 17 Trials and Pharmacovigilance, Instituto Butantan. Av. Vital Brasil 1500. São Paulo, Brazil, 05503-900. Phone:
- **18** +55(21) 97035-8843.
- 19 E-mail: jose.amoreira @butantan.gov.br
- 20 Keywords: CoronaVac; Adverse Events Following Immunization; Covid-19 vaccine; Adult vaccination; Active
- 21 Pharmacovigilance, Phase IV trial, Covid-19
- 22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 23 Abstract

Objective: This Phase IV prospective observational study aimed to evaluate the safety and
monitor adverse events following immunization (AEFI) associated with CoronaVac, an
inactivated SARS-CoV-2 vaccine, in Brazilian adult (18-59 years) and elderly (≥60 years)
populations.

Methods: Participants (n=538; 487 adults and 51 elderly) were enrolled from three public health services in São Paulo, Brazil. A two-dose vaccination regimen, administered 14 days apart, was used. The study assessed Adverse Reactions (AR) necessitating medical attention within seven days post-vaccination dose and monitored AEFI for a period of 42 days. Safety was monitored through a review of participant diary cards, telephone contacts, and on-site study visits.

Results: Among adults, the most frequently reported local AR after the first and second dose was pain (256[52.6%] and 129 [29.5], respectively), while the most common systemic reaction was a headache (158[34.5%] and 51 [11.6%], respectively). Most local and systemic solicited ARs were of Grade 1 or 2, with these reactions being more prevalent in adults after the first dose. One serious adverse event possibly related to the vaccine was reported among adults, but there were no fatalities. Nine adult participants experienced adverse events of special interest, which included five cases of Covid-19.

41 Conclusion: CoronaVac demonstrated safety and tolerability in the observed population.
42 Ongoing post-marketing surveillance is crucial for the identification of rare adverse events and
43 further affirmation of the vaccine's safety profile.

## 44 ClinicalTrials.gov Identifier: NCT04845048

## 46 Introduction

The swift development of SARS-CoV-2 vaccines and their subsequent rapid market authorization process in response to the Covid-19 pandemic has underscore the importance of pharmacovigilance. This practice manages the substantial number of reported suspected adverse events following immunization (AEFI) and its implications for the global vaccination campaign [1].

Instituto Butantan (IB), a Brazilian public biomedical research and manufacturing institution, has played a pivotal role in Covid-19 governance in Brazil. In 2020, IB initiated a phase 3 clinical trial to evaluate efficacy and safety of CoronaVac in first-line healthcare professionals in Brazil [2]. In January 17<sup>th</sup>, CoronaVac was granted Emergency Use Authorization (EUA) by the National Health Surveillance Agency (ANVISA).

However, the large participants samples in a phase 3 trial have limitations in detecting rare adverse events. Routine pharmacovigilance activities typically depend on spontaneous reporting, which highlights the crucial role of post-marketing safety surveillance in prioritizing vaccine rollout and equitable access. Following ANVISA recommendations, IB undertook a post-market approval safety evaluation to characterize AEFI associated with CoronaVac in adults and the elderly during the vaccination campaign in Brazil.

# 63 Methods

64 Study design and setting

65 This phase IV prospective observational study monitored the safety of CoronaVac after a 66 minimum of 1-dose administration. The study, registered on clinicaltrials.org prior to data 67 acquisition (NCT04845048), was conducted from May 2021 to January 2022 across three 68 public health services, in São Paulo state, Brazil. The study commenced after ANVISA issued

69 an EUA for CoronaVac on January 17th, 2021. Ethical approval was obtained from the 70 coordinating study site (University of São Paulo, protocol number: 4.684.670) and the collaborating study sites - Centro de Referência de Imunobiológicos Especiais/Hospital das 71 72 Clínicas da Faculdade de Medicina da Universidade de São Paulo (CRIE-HCFMUSP). Centro 73 de Saúde Escola da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP-USP), and Centro de Saúde Escola da Faculdade de Medicina de Botucatu – Unesp. 74 75 Written informed consent was obtained from all study participants according to local IRBs. We reported as per the Strengthening the Reporting of Observational Studies in Epidemiology 76 77 (STROBE) guideline (refer to Supplementary appendix).

78 Participants

79 Eligible participants for the CoronaVac vaccine, aged 18-59 years-old (adults) and > 60 years (elderly), were recruited based on the criteria of the national immunization program in Brazil 80 during the study [3]. Potential participants were invited to join the study, with participation 81 contingent on signing an informed consent form and agreement to adhere to study procedures. 82 Individuals with a history of allergic reactions or anaphylaxis to previous immunizations, 83 84 allergy to any CoronaVac component, fever (axillary temperature  $\geq 37.8^{\circ}$  C) within 72 hours 85 prior to vaccination, or unavailable throughout the study period (42 days or 60 days in case of women with childbearing potential) were considered ineligible 86

87 Primary and secondary endpoints

The primary safety endpoint entailed the characterization of adverse reactions requiring medical care and assistance within 7 days post-administration of any of the two CoronaVac doses (14 days apart). The secondary endpoints encompassed: 1) characterization of AEFI requiring medical attention within 42 days post-administration of any dose, considering incidence, causality, and seriousness; 2) characterization of adverse reactions within 30

minutes post-administration of any dose, considering incidence and seriousness, 3)
characterization of serious adverse event (SAE) within a 42-day period post-administration of
any dose of the vaccine, stratified by age group, and 4) profiling of adverse event of special
interest (AESI) within a 42-day period post-administration of any dose of the vaccine, stratified
by age group. Adverse events were categorized on dose incidence, causality, severity, and age
group. The exploratory endpoints included documenting adverse events among pregnant
women and their exposed infants.

100 Study procedures for active surveillance

101 The study entailed two visits to the clinical centers (V1 -initial screening and first dose 102 vaccination; V2 - second dose vaccination and surveillance assessment through participant 103 diary card review, and seven telephone contacts (C1 to C7 - for active AE surveillance). If eligible, participants received the first vaccine dose and remaining under observation at the 104 105 clinical center for 30 minutes for immediate hypersensitivity AEFI assessment and solicited 106 AEFI recording (V1 and V2). Clinical center staff also gathered information concerning 107 demographics (sex, age, and race), medical history, concomitant medication, ongoing 108 pregnancies and infants (where applicable), vaccination site (right arm/left arm/other), administration route (intramuscular/other) and volume (0.5mL/other), vaccine batch, 109 110 manufacturing date and expiration date.

After vaccination, each participant was evaluated by study site staff for immediate occurrence of solicited and unsolicited AEFI. Before departing, participants received a diary card for solicited and unsolicited adverse events up to 7 days post-vaccination, a device for measuring local site AEFI, a thermometer, and instructions for use. Participants were further instructed to return to the study site for a second visit (V1 + 14 days tolerance), respond to scheduled telephone calls [C1 (V1 + 3-5 days) and C2 (V1 + 7-9 days)], and promptly notify study staff

117 in the event of hospitalization and/or SAE. Participants were also provided instructions on how 118 to record AEFIs and assess the severity/intensity of the AEFIs using a simple scoring system. AEFIs occurring during pregnancy or related to newborns were documented, if applicable. 119 120 Information regarding AEFIs recorded in participant diary card and solicited AEFIs were collected by the sites during subsequent telephone contacts [C3 (V2 + 3-5 days), C4 (V2 + 7-121 122 9 days), C5 (V2 + 14-16 days), C6 (V2 + 42-45 days) and C7 – end of study (V2 + 60-63) days)]. During the second visit (V1 + 14 - 31 days), participants underwent physical 123 124 examination and concomitant medication review. Possible pregnancy information was 125 gathered, if applicable. Data recorded in the participant dairy cards were scrutinized by site 126 center medical staff.

## 127 Safety assessment

128 In this context, an adverse event was defined as any undesirable medical occurrence that 129 affected a vaccinated participant, regardless of its causal relationship to the vaccine. 130 Consequently, an adverse event could comprise any unfavorable and unintended sign, symptom, or disease (including an abnormal laboratory findings), temporally associated with 131 132 the vaccination. All adverse events were encoded and categorized in accordance with the Medical Dictionary for Regulatory Activities (MedDRA, version 24.0) [3]. A Serious Adverse 133 134 Event (SAE) was characterized as any adverse event resulting in outcomes such as death, a 135 life-threatening condition, the necessity for hospitalization or an extension of an existing hospitalization, significant or persistent incapacitation, congenital anomaly, any suspected 136 137 transmission of an infectious agent through a medicinal product, or any clinically significant 138 adverse event. An Adverse Reaction (AR) was defined as any AE with a plausible causal relationship with the vaccine, as determined by the adapted classification of the Uppsala 139 140 Monitoring Centre (UMC) of the World Health Organization (WHO) [4][5]. An adverse event

of special interest was a predefined, medically significant event that might potentially be
causally associated with a vaccine product, warranting close monitoring and confirmation via
additional specific studies [6].

The severity of an AE was classified from grade one to four according to the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials of the US Food and Drug Administration (FDA) [7]. The study staff was instructed to incorporate the following information in their AE evaluations: the classification of seriousness; the classification of severity [4], causality assessment, and adverse event outcome (Supplementary information).

The definitions and classifications of adverse events were in accordance with the recommendations stipulated by the Good Clinical Practices (GCP) [8], the Guideline on Clinical Safety Data Management from the International Conference on Harmonization (ICH) [5], and the Brighton Collaboration's guidance on safety data collection for COVID-19 vaccine safety [6]. In instances where case definitions were not provided by Brighton Collaboration sources, the Common Terminology Criteria for Adverse Events (CTCAE) issued by the US Department of Health and Human Services [9] were utilized as reference.

157 *Study vaccine* 

The study vaccine is an inactivated whole-virion vaccine with aluminum hydroxide serving as the adjuvant, prepared with a novel coronavirus strain (CZ02 strain) inoculated in African green monkey kidney cells (Vero cells) [10]. The inactivation process involved adding  $\beta$ propiolactone to the virus harvest fluid at a ratio of 1:4000 and inactivating at 2-8° C for 12-24 h. A single dose of the vaccine contains 3 µg of SARS-CoV-2 virion in a 0.5 mL aqueous suspension for injection with 0.45 mg/mL of aluminum. The vaccine was administered in two doses, delivered 14 days apart, intramuscularly in the deltoid muscle. The vaccine is free of

preservatives and the final packaging includes a single-dose vial with an extractable volume of
0.5 mL, a vial with two doses of 0.5 mL each, or a multi-dose vial containing 5 mL, with each
vaccine dose corresponding to 0.5 ml.

168 Sample size estimation

The sample size was estimated following the recommendation of the Guide to Clinical Evaluations of New Vaccines (EMEA/CHMP/VWP/164653/2005) [11], suggesting that at least 100 participants from each vaccination target group should have AEFI monitored. Thus, a sample of 900 vaccinated participants (600 adults and 300 elderly) was estimated for the evaluation of solicited and unsolicited AEFI through active surveillance.

This sample size was based on the formula presented below, assuming the observation of an AE at an established minimum frequency equal to M (maximum risk).  $N = ln(\alpha)/ln(1-M)$  Type I error parameter ( $\alpha$ ) adopted was 5% (two-tailed) and N for elderly=300, to achieve AE frequency detection of approximately 1% (maximum risk of 1 to 100), whereas N for adults= 600 achieves AE frequency at a maximum risk of 1 in 200.

179 Statistical analysis

180 Descriptive statistical data analysis of AE and AR was performed, stratified by study groups 181 (younger and older adults) and dose vaccination [12]. Results are presented as the frequency 182 of occurrence (absolute and percentage values) for qualitative variables and as dispersion 183 measures (quartiles) for quantitative variables. Missing data were handled with the list-wise 184 deletion method. The statistical analyses were conducted using Stata (Stata-Corp LP, College 185 Station, Texas USA), version 13.0, for Windows.

# 186 **Results**

# 187 Participants

Figure 1 presents the study participants' flowchart, segmented to age groups. The study incorporated a total of 538 participants, where young adults represented 90.5% (487/538) of the sample and older adults constituted 9.5% (51/538). Table 1 provides a description of the participants' baseline socio-demographic characteristics. The median age for young adults was 30.5 years, and for the oldest adults, its was 65.3 years. The majority of participants were female (57.1%) and identified as white (59.3%).

The median occurrence of AE and AR per participant was three following the first dose, and varied from one to three following the second-dose., across the entire population (Table 2). Both AE and AR were more frequent in the 18-59-year-old group after the first dose (V1). Only one SAE was reported as possibly related to vaccination, with no registered cases of death or permanent impairment. The AE and AR were more frequent after V1 in the 18–59-year-old group.

200 Primary endpoint

For adults, considering the primary endpoints, 76.0% experienced solicited AR after the first dose, and 42.5% after the second dose, within a 7-day post-vaccination period (Table 3). The most common local AR after both doses was pain at the administration site (256 [52.6%] and 129 [29.5%], respectively). The majority of local and systemic solicited AR were classified as Grade 1 or Grade 2 (Table S1). Thirty-five cases (3.0%) were classified as Grade 3 after the first dose, while 10 cases (2.6%) after the second. Only three ARs were classified as Grade 4 (1 headache, 1 fatigue and 1 myalgia), all following the first dose.

For the elderly, considering the primary endpoints, 43.1% experienced solicited AR after the first dose, and 44.0 % after the second dose, within a 7-day post-vaccination period (Table 4).

The most common local AR was pain at the administration-site (9 [17.7%] and 11 [22.0%] after first and second dose, respectively) and the most frequent systemic AR one was headache (9 [17.7%] and 10 [20.0%] after first and second dose, respectively). The majority of local and systemic solicited AR were classified as Grade 1 or Grade 2 (Table S2). Only one episode of myalgia was classified as Grade 3, no local and systemic solicited AR were classified as Grade 4.

Frequency and severity of solicited and unsolicited AR within 7-days post-vaccination foradults and elderly are available in the Supplementary material (Table S1 and Table S2).

218 Secondary endpoint

Table 5 displays the frequency of adults and elderly experiencing solicited AR 30 minutes post each vaccination. The solicited AR were more common after the first dose among adults (129 [26.5%] vs 84 [19.2%]). Data suggests that solicited AR were less frequent among the elderly, with no noticeable difference between the first and the second dose (6 [11.8%] and 6 [12.0%], respectively). The frequency and intensity of unsolicited AR 30 minutes post-vaccination in adults and elderly can be found in the Supplementary material (Table S3).

The frequency of AR that required medical intervention and the SAE 42-days post vaccination are outlined in Table S4. There were no SAE reports in the elderly group. Only one SAE (migratory polyarthralgia) was assessed by the Investigator and considered possibly related to the vaccine. All participants that presented any AR that required medical intervention or SAE had fully recovered.

Nine adult participants experienced AESI. These included five cases of Covid-19, two cases of
arthritis, one case of tachycardia, and one case of acute renal failure. The frequency, causality
assessment and intensity of the AESI can be found at Supplementary material (Table S5).

# 233 Exploratory endpoints

Among pregnant participants (n=2), seven non-serious AR were reported. All these cases recovered. Detailed information about the AE in pregnant women and infants can be found in Supplementary material (Table S6).

## 237 DISCUSSION

The expedited development and EUA of Covid-19 vaccines have been instrumental in mitigating the global impact of the SARS-CoV-2 pandemic, especially during its acute phase [13]. Among these vaccines, CoronaVac, developed by Sinovac Biotech and later transferred to IB, has been extensively utilized in numerous countries. However, upon EUA, safety data for CoronaVac, as with all Covid-19 vaccines authorized during this public health crisis, were limited, thus necessitating rigorous post-vaccination real-world safety data.

The ANVISA recognizing this knowledge gap commissioned a comprehensive post-244 245 authorization safety study on CoronaVac in adults and elderly populations. The aim was to 246 document its safety profile, particularly focusing on the identification and characterization of 247 AEFI among adults and the elderly populations. The real-world nature of this study offered the opportunity to evaluate the vaccine's safety profile in a broader and more diverse population 248 than those included in clinical trials. Our findings suggest that most AE and AR following 249 250 vaccination were mild to moderate in severity and resolved spontaneously. The frequency of 251 AR, solicited and unsolicited, was greater in younger adults than in elderly, especially after the 252 first dose. Only one SAE was reported, suggesting a satisfactory safety profile of the vaccine.

Brazilian national passive surveillance data reported a 6.6% rate of SAE following CoronaVac
[14], whereas our study identified a significantly lower rate of 0.6%. Unlike passive
pharmacovigilance, which relies on voluntary spontaneous reporting of AE, active

pharmacovigilance facilitates the procurement of more detailed safety information. The passive surveillance is more sensitive to SAE, but the data quality is weak [15][16]. A strength of our research is the active surveillance of AEFI by follow-up phone calls after each dose. This procedure made possible to capture more detailed mild and moderate events, which are typically underreported in passive surveillance systems [15]. Another strength of this study is the low dropout rate, which reinforces the good tolerability of the vaccine. Additionally, the participants presented different risk levels of exposure to Covid-19.

263 Our study has limitations. Sample size did not reach the previously calculated number of 264 participants because the public vaccination campaign started 3 months earlier than the protocol 265 approval, including other vaccines rather than CoronaVac. Due to this difficulty to include unvaccinated subjects, and therefore, the reduction in sample size, the minimum of AE 266 detection power for adults was  $M=1/165\approx0.6\%$  whereas for elderly was  $M=1/18\approx5.7\%$ . The 267 demographic distribution of the sample population, which had a considerably larger 268 269 representation of younger adults than older ones might potentially introduce some bias in the 270 results and explain the observed higher vaccine reactogenicity in the younger adults compared 271 to older ones. After CoronaVac's EUA extension to the pediatric population in January 20<sup>th</sup>, 272 2022, a protocol amendment was made to include children and adolescents, enabling safety information collection for this group. Albeit the above sample size limitations, our data are 273 274 consistent with other studies that suggest CoronaVac are well tolerated with a relatively lower frequency of AE regardless of age [10] [17] [18]. 275

Our findings showed that the majority of ARs were mild to moderate [Grade 0 and Grade 1: (962/1157 - 83.1%)], which coincides with previous reports evaluating this vaccine [10] [17] [18]. Most AE were low grade and resolved spontaneously, supporting the findings reported by Tanriover et al. [10] and Wu et al. [19] in Turkey and China, respectively. Most of the

280 solicited AR reported by the participants lasted less than a day, differently from data in Xia et 281 al. [20] as well as Zhang et al. [21] studies which reported adverse reactions lasting for up to 282 72h after the complete schedule of vaccine administration in healthy adults. Most common 283 adverse events reported in our study, such as local pain, headache, and myalgia, were also 284 observed in other studies evaluating CoronaVac and are listed in the vaccine package insert. Regarding the most frequent local and systemic adverse reactions by inactivated virus Covid-285 286 19 vaccine, Ling et al. [22] reported pain, swelling, and fever at the injection site, whereas Chen 287 et al. [23] reported pain, swelling and redness at the injection site. Systemic AEFI such as 288 headache (34.5%) and fatigue (21.97%) predominated in our study. Results from randomized 289 trials in Indonesia have listed headache and malaise as the most significant systemic AEFI [24]. 290 Indonesian results pointed out gender related AEFI after CoronaVac immunization in which 291 females presented higher frequency of AEFI than male participants.

Our study adds to the growing body of evidence on the safety of SARS-CoV-2 vaccines, particularly CoronaVac. It equips clinicians with pertinent information for patient counseling about potential CoronaVac side effects and provides policymakers with crucial data to inform vaccination strategies and campaigns. In fact, our data helped consolidate the safety profile of CoronaVac in the Brazilian's Covid-19 vaccine response plan.

In conclusion, our data substantiate the overall safety of the CoronaVac in adults and elderly
individuals, with side effects being generally mild and transient. However, continuous
monitoring for rare AE remains crucial. These findings should bolster confidence in
CoronaVac among clinicians, policymakers, and the public, while encouraging further research
on Covid-19 vaccines in various demographic and epidemiological settings.

# 302 Acknowledgments

We thank the study volunteers. The study's conception, design, conduct, analysis, and interpretation, as well as the drafting and submission of this manuscript, involved the IB staff. The corresponding author had full access to the study data and had final responsibility for the decision to submit for publication.

# 307 Declarations

308 Funding: This study was sponsored by Fundação Butantan (FB).

309 Consent to participate: All participants gave informed consent to participate in this study,

310 where publication was identified as one form of dissemination. Information and Study Consent

- 311 Forms available upon request.
- 312 Ethics approval: Approval for this research was granted by the Ethical Committee of the313 University of São Paulo (protocol number: 4.684.670).
- 314 Conflict of interest: JM is Associate Editor for PLoS One. MC, VI, AL, LR, PB, MS, ML, MO,

315 VG, JM, and FB are current employees of Instituto Butantan. EF is a former employee of

316 Instituto Butantan. ASS, MHL and PJFVB were principal investigators.

- 317 Data availability: All data are available in the text and in the supplementary appendix for318 consultation.
- 319
- 320
- 321

#### 322 References

- Rudolph A, Mitchell J, Barrett J, Sköld H, Taavola H, Erlanson N, Melgarejo-González
   C, Yue QY. Global safety monitoring of COVID-19 vaccines: how pharmacovigilance
   rose to the challenge. *Ther Adv Drug Saf.* 2022 Aug 25; 13:20420986221118972. doi:
   10.1177/20420986221118972.
- 2. Palacios R, Patino EG, Piorelli RdO, et al. Double-blind, randomized, placebocontrolled phase III clinical trial to evaluate the efficacy and safety of treating
  healthcare professionals with the adsorbed COVID-19 (inactivated0 vaccine
  manufactured by Sinovac PROFISCOV: a structured summary of a study protocol for
  a randomized controlled trial. *Trials*. 2020; 21(1): 853.
- 332 3. MedRA dictionary International Conference on Harmonization. The medical dictionary
   333 for regulatory activities. <u>https://www.meddra.org/</u>.
- WHO/UMC/ The use of the WHO-UMC system for standardised case causality
   assessment [Internet]. Uppsala: The Uppsala Monitoring Centre. <u>http://www.who-</u>
   umc.org/Graphics/24734.pdf.
- 5. ICH Clinical Safety Data management: Definitions and Standards for Expedited
  Reporting [Internet]. Genebra: International Conference on Harmonisation of
  Technical Requirements or Registration of Pharmaceuticals for Human Use; 2003.
  E2A. Accessed on 12 February 2019.
  https://www.ich.org/fileadmin/Public\_Web\_Site/ICH\_Products/Guidelines/Efficacy/E
- 342 <u>2D/Step4/E2D\_Guideline.pdf</u>.
- 343 6. World Health Organization (WHO) Global manual on surveillance of adverse events
  344 following immunization 2014/2016,
  345 <u>https://apps.who.int/iris/rest/bitstreams/914830/retrieve</u>. Accessed on 12 December
  346 2021.

- 347 7. CBER/USFDA/USDHHS Guidance for Industry: Toxicity Grading Scale for Healthy
- 348 Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
- 349 [Internet]. Silver Spring: US Food and Drug Administration; 2007 [cited 2011 Set 29].
- 350 http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegula
- 351 toryInformation/Guidances/Vaccines/ucm091977.pdf.
- 8. European Medicines Agency. Integrated addendum to ICH E6Rr1: guideline for good
  clinical practice E6(R2). London: EMA; 2016. [cited 2018 Jul 2].
- 354 <u>https://www.ich.org/fileadmin/Public\_Web\_Site/ICH\_Products/Guidelines/Efficacy/E</u>
- 355 <u>6/E6\_R2\_Step\_4\_2016\_1109.pdf</u>.
- NIC/NIH NCI Common Terminology Criteria for Adverse Events (CTCAE) [Internet].
   http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
- 358 10. Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated
  359 whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind,
  360 randomised, placebo-controlled, phase 3 trial in Turkey; *Lancet*. 2021;
  361 398(10296):213-222.
- 362 11. Rego GNA, Nucci MP, Alves AH, Oliveira LCM, Nucci LP, Mamani JB, Gamarra LF.
   363 Current Clinical Trials Protocols and the Global Effort for Immunization against SARS 364 CoV-2. *Review Vaccines*. 2020; 8, 474.
- 36512. Ministério da Saúde, Brasil. 2021. Manual De Vigilância Epidemiológica De Eventos
- 366 Adversos Pós-Vacinação. 4th edition. <u>https://www.gov.br/saude/pt-br/centrais-de-</u>
   367 conteudo/publicacoes/publicacoes-svs/vacinacao-imunizacao-pni/manual eventos-
- 368 adversos pos vacinacao 4ed atualizada.pdf/ accessed on 20 October, 2022.
- 369 13. Grana C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines.
   370 *Cohrane Database Syst Rev.* 2022; 12(12):CD015477.
- 14. Ministério da Saúde, Brasil. 2021. Manual De Vigilância Epidemiológica De Eventos
- 372 Adversos Pós-Vacinação. 4th edition. <u>https://www.gov.br/saude/pt-br/centrais-de-</u>

373	conteudo/	publicacoes/	publicacoes-svs/	vacinacao-	imunizacao-	oni/manual	eventos-

adversos pos vacinacao 4ed atualizada.pdf/ accessed on 20 October, 2022.

# 375 15. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems 376 for vaccine adverse events. Am J Public Health. 1995 Dec;85(12):1706-9. doi: 377 10.2105/ajph.85.12.1706.

- 378 16. CIOMS 2017. CIOMS guide to active vaccine safety surveillance. <u>https://cioms.ch/wp-</u>
   379 content/uploads/2020/04/240WEB-CIOMS-Guide-AVSS-20170202-protected.pdf.
- 380 17. Miyaji KT, Itto LYU, Jacintho LC et al. Adverse events following immunization of
  381 elderly with COVID-19 inactivated virus vaccine (CoronaVac) in Southeastern Brazil:
- an active surveillance study. *Rev Inst Med Trop Sao Paulo*. 2022; 64: e56.
- 383 18. Makadzange AT, Gundidza P, Lau C, et al. Vaccine adverse events following COVID-
- 384 19 vaccination with inactivated vaccines in Zimbabwe. *Vaccines (Basel)*. 2022; 10(100:
  385 1767.
- Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and
  immunogenicity of an inactivated SARSCoV-2 vaccine (Coronavac) in healthy adults
  aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2
  clinical trial. *Lancet Infect Dis*. 2021;21:803-12.
- 390 20. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, 391 Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, 392 393 Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. Effect of an Inactivated Vaccine 394 Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 395 Randomized Clinical Trials. JAMA. 2020 8;324(10):951-960. Sep doi: 396 10.1001/jama.2020.15543.
- 21. Zhang YJ, Zeng G, Pan HX, Li CG, Kan B, Hu YL, Mao HY, Xin QQ, Chu K, Han WX,
  Chen Z, Tang R, Yin WD, Chen X, Gong XJ, Qin C, Hu YS, Liu XY, Cui GL, Zhu FC
  (2020b) Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy

- adults aged 18–59 years: report of the randomized, doubleblind, and placebocontrolled phase 2 clinical trial. *medRxiv* 2020b (p. 2020.07.31.20161216). Doi:
  https://doi.org/10.1101/2020.07.31.20161216.
- 403 22. Ling Y, Zhong J, Luo J. Safety and effectiveness of SARS-CoV-2 vaccines: A
  404 systematic review and meta-analysis. *J Med Virol*. 2021 Dec;93(12):6486-6495. doi:
  405 10.1002/jmv.27203. Epub 2021 Jul 26.
- 23. Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, Zou H, Sun C. Safety of SARSCoV-2 vaccines: a systematic review and meta-analysis of randomized controlled
  trials. *Infect Dis Poverty*. 2021 Jul 5;10(1):94. doi: 10.1186/s40249-021-00878-5.
- 409 24. Supangat, Sakinah EN, Nugraha MY, Qodar TS, Mulyono BW, Tohari AI. COVID-19
  410 Vaccines Programs: adverse events following immunization (AEFI) among medical
  411 Clerkship Student in Jember, Indonesia. *BMC Pharmacol Toxicol*. 2021 Oct
  412 12;22(1):58. doi: 10.1186/s40360-021-00528-4.

### 422 Tables and Figure:

- 423 Figure 1. Study flowchart: screening, enrollment, and vaccination.
- 424 Table 1. Demographic characteristics of all participants by study group.
- 425 Table 2. Frequency of Adverse Events and Adverse Reactions after CoronaVac vaccination
- 426 (first and second dose) by study group.
- Table 3. Frequency of solicited adverse reactions (AR) 7 days post vaccination in adults (18 59 years).
- Table 4. Frequency of solicited adverse reactions (AR) 7 days post vaccination in elderly (≥60
- 430 years).
- 431 Table 5. Frequency of Adverse reactions (AR) 30 minutes post vaccination in adults (18 59
- 432 years) and elderly ( $\geq 60$  years).

## 433 **Supporting information captions**

- 434 S1 Table. Frequency and severity of adverse reactions, solicited (local and systemic) and
- unsolicited, occurring up to 7 days after administration of each vaccine dose in adults (18 to
- 436 59 years), according to severity
- 437 S2 Table. Frequency and severity of adverse reactions, solicited (local and systemic) and
- 438 unsolicited, occurring up to 7 days after administration of each vaccine dose in elderly (≥60
- 439 years), according to severity
- 440 S3 Table. Frequency of adverse reactions, solicited (local and systemic) and unsolicited,
- 441 occurring within 30 minutes after administration of each vaccine dose in a) adults (18-59
- 442 yeas) and b) elderly (≥60 years), according to severity
- 443 S4 Table. Frequency of solicited (local and systemic) and unsolicited adverse reactions
- 444 which required medical attention, occurring at any time within 42 days after administration of
- each vaccine dose in a) adults (18-59 years) and b) elderly (≥60 years), according to
- 446 severity

- 447 S5 Table. Serious adverse events and adverse events of special interest according to the
- 448 administration dose regarding description (MedRA code), causality, severity, predictability
- 449 and outcomes
- 450 S6 Table. Adverse event details observed in pregnant women and newborn according to the
- 451 administration dose regarding description code (MedRa), causality, severity, predictability
- 452 and outcomes




Figure 1. Study flowchart: screening, enrollment, and vaccination.

VARIABLES	18 -	Adults 59 years old	≥6	Elderly 0 years old	TOTAL (N=538)		
		(n=487)		(n=51)			
Age (years)							
Median (Q1 - Q3)	30.5	(25.5 - 41.6)	65.3	(64.2 - 68.9)	32	(26.0 - 46.0)	
Sex, n (%)							
Female	276	(56.7)	31	(60.8)	307	(57.1)	
Male	211	(43.3)	20	(39.2)	231	(42.9)	
Ethnicity, n (%) axiv preprint doi: https://doi.org/10.1101/2023.08.19.23 int (which way inprocertified by peer review) is the a	294316; this version uthor/funder, who perpetuity.	on posted August 23, 2023. T has granted medRxiv a licen	he copyright h se to display th	older for this he preprin(158.8)	319	(59.3)	
Black It is made available und	der a $CC-By01.0$ In	ternationa license	8	(15.7)	58	(10.8)	
Multiracial	125	(25.7)	7	(13.7)	132	(24.5)	
Indigenous	1	(0.2)	3	(5.9)	4	(0.7)	
Asian	11	(2.3)	3	(5.9)	14	(2.6)	
Other	11	(2.3)	0	(0.0)	11	(2.0)	
Clinical Sites, n (%)						-	
Site 01	216	(44.4)	35	(68.6)	251	(46.7)	
Site 02	180	(37.0)	16	(31.4)	196	(36.4)	
Site 03	91	(18.7)	0	(0.0)	91	(16.9)	

Table 1. Demographic characteristics of all participants by study group.

Q1: first quartile; Q3: third quartile

		1st DOSE			2nd DOSE						
STUDY GROUP	AE Participants with AE		AE per j	oarticipant	AE	Participants with AE	AE per j	participant			
	n	1 (0()		median (Q1-Q3)		n/n <sub>total</sub> (%)	median	(Q1-Q3)			
Adults (18 - 59 years)	1569	392/487 (80.5)	3	(2 - 5)	554	218/438 (49.8)	2	(1 - 3)			
Elderly (≥60 years)	136	30/51 (58.8)	3	(1 - 6)	94	28/50 (56.0)	3	(1 - 5)			
TOTAL	1705	422/538 (78.4)	3	(2 - 5)	648	246/488 (50.4)	2	(1 - 3)			
STUDY GROUP	AR	Participants with AR	AR per participant		AR	Participants with AR	AR per participant				
STUDT GROUT	n	n/n <sub>total</sub> (%)	median	$(Q_1 - Q_3)$	n	n/n <sub>total</sub> (%)	median	(Q <sub>1</sub> -Q <sub>3</sub> )			
Adults (18 - 59 years)	1288	374/487 (76.8)	3	(1 - 5)	438	194/438 (44.3)	2	(1 - 3)			
Elderly (≥60 years)	84	23/51 (45.1)	3	(1 - 4)	53	22/50 (44.0)	1	(1 - 4)			
TOTAL	1372	397/538 (73.8)	3	(1 - 5)	491	216/488 (44.3)	2	(1 - 3)			

Table 2. Frequency of Adverse Events and Adverse Reactions after Coronavac vaccination (first and second dose) by study group.

Q1: first quartile; Q3: third quartile

AE: Adverse Event

AR: Adverse Reaction

		1st DO	2nd DOSE				
Solicited Adverse Reactions (AR)	AR Adults (n=487)		AR Total		Adults =438)	AR Total	
			n	n	%		
Local							
Pain	256	52.6	263	129	29.5	132	
Erythema	9	1.8	9	10	2.3	11	
Swelling	15	3.1	15	3	0.7	4	
Induration	10	2.1	11	3	0.7	3	
Pruritus	15	3.1	15	4	0.9	4	
Tendemess	166	34.1	169	59	13.5	59	
Systemic							
Decreased appetite	20	4.1	20	6	1.4	7	
Arthralgia	40	8.2	44	11	2.5	11	
Chills	35	7.2	37	9	2.1	9	
Headache	168	34.5	191	51	11.6	54	
Diarrhea	36	7.4	38	14	3.2	15	
Rash	8	1.6	8	1	0.2	1	
Fatigue	107	22.0	127	23	5.3	25	
Fever (Pyrexia)	14	2.9	14	5	1.1	5	
Hypersensitivity (Allergic Reaction)	2	0.4	2	0	0.0	0	
Myalgia	69	14.2	72	21	4.8	22	
Nausca	39	8.0	43	16	3.7	17	
Pruritus Outside the Administration Site	32	6.6	33	5	1.1	5	
Cough	38	7.8	39	5	1.1	5	
Vomiting	6	1.2	7	2	0.5	2	
TOTAL SOLICITED	370	76.0	1157	186	42.5	391	

Table 3. Frequency of solicited adverse reactions (AR) 7 days post vaccination in adults (18 - 59 years).

		1st 1		2nd DOSE			
Solicited Adverse Reactions (AR)		Elderly n=51)	AR Total		Elderly n=50)	AR Total	
	n	%	n	n	%	n	
Local							
Pain	9	17.6	10	11	22,0	11	
Swelling	0	0.0	0	1	2.0	1	
Itching	1	2.0	1	2	4.0	2	
Tendemess	8	15.7	8	1	2.0	1	
Systemic							
Decreased Appetite	1	2.0	1	0	0,0	0	
Arthralgia	7	13.7	9	4	8.0	4	
Chills	3	5.9	4	4	8.0	6	
Headache	9	17.6	9	10	20.0	12	
Diarrhea	3	5.9	3	2	4.0	2	
Rash	1	2.0	1	2	4.0	2	
Fatigue	7	13.7	7	1	2.0	1	
Fever (Pyrexia)	0	0.0	0	1	2.0	1	
Myalgia	8	15.7	8	3	6.0	3	
Nausca	2	3.9	2	2	4.0	2	
Pruritus Outside the Administration Site	4	7.8	4	1	2.0	1	
Cough	1	2.0	1	1	2.0	1	
Vomiting	1	2.0	1	0	0.0	0	
TOTAL SOLICITED	22	43.1	69	22	44.0	50	

Table 4. Frequency of solicited adverse reactions (AR) 7 days post vaccination in elderly (≥60 years).

	1st DOSE				2nd DOSE			1st I	DOSE	2nd DC		DOSE	
Solicited Adverse Reactions (AR)	AR Adults (n=487)		AR Total	AR Adults (n=438)		AR Total	AR Elderly (n=51)		AR Total	AR Elderly (n=50)		AR Total	
	n	%	n	n	%	n	n	%	n	n	%	n	
Local													
Pain	85	17.5	85	52	11.9	52	4	7.8	4	6	12.0	6	
Erythema	2	0.4	2	2	0.5	2	0	0.0	0	0	0.0	0	
Induration	5	1.0	5	3	0.7	3	0	0.0	0	0	0.0	0	
Itching	1	0.2	1	1	0.2	1	0	0.0	0	1	2.0	1	
Tendemess	48	9.9	48	32	7.3	32	2	3.9	2	1	2.0	1	
Systemic													
Arthralgia	0	0.0	0	1	0.2	1	0	0.0	0	1	2.0	1	
Headache	9	1.8	9	4	0.9	4	1	2.0	1	0	0.0	0	
Fatigue	3	0.6	3	3	0.7	3	0	0.0	0	0	0.0	0	
Myalgia	3	0.6	3	1	0.2	1	0	0.0	0	0	0.0	0	
Nausea	3	0.6	3	2	0.5	2	0	0.0	0	0	0.0	0	
Cough	1	0.2	1	1	0.2	1	0	0.0	0	0	0.0	0	
Vomiting	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	
TOTAL SOLICITED	129	26.5	160	84	19.2	102	6	11.8	7	6	12.0	9	

Table 5. Frequency of Adverse Reactions (AR) within 30 minutes post vaccination in adults (18 - 59 years) and elderly (≥60 years).